Article Details

Innate Pharma: First Patient Dosed in Monalizumab Phase 3 Lung Cancer Clinical Trial ...

Retrieved on: 2022-05-01 21:28:56

Tags for this article:

Click the tags to see associated articles and topics

Innate Pharma: First Patient Dosed in Monalizumab Phase 3 Lung Cancer Clinical Trial .... View article details on HISWAI: https://pipelinereview.com/index.php/2022050180767/Antibodies/Innate-Pharma-First-Patient-Dosed-in-Monalizumab-Phase-3-Lung-Cancer-Clinical-Trial-Triggers-%2450M-Payment-From-AstraZeneca.html

Excerpt

MARSEILLE, France I April 29, 2022 I Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that ...

Article found on: pipelinereview.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up